Research ArticleOriginal Research

Are Amphetamines Associated with Adverse Cardiovascular Events Among Elderly Individuals?

James R. Latronica, Taylor J. Clegg, Wen-Jan Tuan and Curtis Bone
The Journal of the American Board of Family Medicine November 2021, 34 (6) 1074-1081; DOI: https://doi.org/10.3122/jabfm.2021.06.210228

References

  1. 1.↵
    1. Farzam K,
    2. Faizy RM,
    3. Saadabadi A
    . Stimulants. In: StatPearls. StatPearls Publishing; 2021. Updated August 6, 2021. Available at: http://www.ncbi.nlm.nih.gov/books/NBK539896/. Accessed March 9, 2021.
  2. 2.↵
    1. Calipari ES,
    2. Ferris MJ
    . Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci 2013;33:8923–5.
    OpenUrlFREE Full Text
  3. 3.↵
    1. Safer DJ
    . Recent trends in stimulant usage. J Atten Disord 2016;20:471–7.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Piper BJ,
    2. Ogden CL,
    3. Simoyan OM,
    4. et al
    . Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLOS ONE 2018;13:e0206100.
    OpenUrl
  5. 5.↵
    1. Berman SM,
    2. Kuczenski R,
    3. McCracken JT,
    4. London ED
    . Potential adverse effects of amphetamine treatment on brain and behavior: a review. Mol Psychiatry 2009;14:123–42.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Rajeh A,
    2. Amanullah S,
    3. Shivakumar K,
    4. Cole J
    . Interventions in ADHD: a comparative review of stimulant medications and behavioral therapies. Asian J Psychiatr 2017;25:131–5.
    OpenUrl
  7. 7.↵
    1. Arnsten AFT
    . Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology 2006;31:2376–83.
    OpenUrlCrossRefPubMedWeb of Science
  8. 8.↵
    1. Hechtman L,
    2. Abikoff H,
    3. Klein RG,
    4. et al
    . Academic achievement and emotional status of children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 2004;43:812–9.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Grimmsmann T,
    2. Himmel W
    . The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany. Eur J Clin Pharmacol 2021;77:107–15.
    OpenUrl
  10. 10.↵
    1. Dalsgaard S,
    2. Kvist AP,
    3. Leckman JF,
    4. Nielsen HS,
    5. Simonsen M
    . Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: a nationwide prospective cohort study. J Child Adolesc Psychopharmacol 2014;24:302–10.
    OpenUrl
  11. 11.↵
    1. Hammerness PG,
    2. Karampahtsis C,
    3. Babalola R,
    4. Alexander ME
    . Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf 2015;14:543–51.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Habel LA,
    2. Cooper WO,
    3. Sox CM,
    4. et al
    . ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011;306:2673–83.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Holick CN,
    2. Turnbull BR,
    3. Jones ME,
    4. Chaudhry S,
    5. Bangs ME,
    6. Seeger JD
    . Atomoxetine and cerebrovascular outcomes in adults. J Clin Psychopharmacol 2009;29:453–60.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Westover AN,
    2. Nakonezny PA,
    3. Haley RW
    . Acute myocardial infarction in young adults who abuse amphetamines. Drug Alcohol Depend 2008;96:49–56.
    OpenUrlCrossRefPubMedWeb of Science
  15. 15.↵
    1. Westover AN,
    2. McBride S,
    3. Haley RW
    . Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiatry 2007;64:495–502.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Diaconu CC,
    2. Dediu GN,
    3. Iancu MA
    . Drug-induced arterial hypertension – a frequently ignored cause of secondary hypertension: a review. Acta Cardiologica 2018;73:511–7.
    OpenUrl
  17. 17.↵
    1. Stone NJ,
    2. Robinson JG,
    3. Lichtenstein AH
    , American College of Cardiology/American Heart Association Task Force on Practice Guidelines, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 2014;63:2889–934.
    OpenUrlFREE Full Text
  18. 18.↵
    1. Cheitlin MD
    . Cardiovascular physiology-changes with aging. Am J Geriatr Cardiol 2003;12:9–13.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Palombo C,
    2. Kozakova M
    . Arterial stiffness, atherosclerosis and cardiovascular risk: Pathophysiologic mechanisms and emerging clinical indications. Vascul Pharmacol 2016;77:1–7.
    OpenUrlCrossRef
  20. 20.↵
    1. Stiefel G,
    2. Besag FMC
    . Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf 2010;33:821–42.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Westover AN,
    2. Halm EA
    . Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review. BMC Cardiovasc Disord 2012;12:41.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Michielsen M,
    2. Kleef D,
    3. Bijlenga D,
    4. et al
    . Response and side effects using stimulant medication in older adults with ADHD: an observational archive study. J Atten Disord 2021; 1712–91.
  23. 23.↵
    1. Kalbag AS,
    2. Levin FR
    . Adult ADHD and substance abuse: diagnostic and treatment issues. Subst Use Misuse 2005;40:1955–81.
    OpenUrlPubMed
  24. 24.↵
    1. Dennis JA,
    2. Gittner LS,
    3. Payne JD,
    4. Nugent K
    . Characteristics of U.S. adults taking prescription antipsychotic medications, National Health and Nutrition Examination Survey 2013–2018. BMC Psychiatry 2020;20:483.
    OpenUrl
  25. 25.↵
    American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. J Amer Geri Soc 2015;63:2227–46.
    OpenUrl
  26. 26.↵
    1. Roose SP,
    2. Schatzberg AF
    . The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol 2005;25:S1–7.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    1. Alexopoulos GS,
    2. Katz IR,
    3. Reynolds CF,
    4. Carpenter D,
    5. Docherty JP
    , Expert Consensus Panel for Pharmacotherapy of Depressive Disorders in Older Patients. The expert consensus guideline series. Pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001;1–86.
  28. 28.↵
    1. Satel SL,
    2. Nelson JC
    . Stimulants in the treatment of depression: a critical overview. J Clin Psychiatry 1989;50:241–9.
    OpenUrlPubMedWeb of Science
  29. 29.↵
    1. Lavretsky H,
    2. Reinlieb M,
    3. St Cyr N,
    4. Siddarth P,
    5. Ercoli LM,
    6. Senturk D
    . Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2015;172:561–9.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Alexopoulos GS
    . Pharmacotherapy for Late-Life Depression. J Clin Psychiatry 2011;72:e04.
    OpenUrlPubMed
  31. 31.↵
    1. Dolder CR,
    2. Nicole Davis L,
    3. McKinsey J
    . Use of Psychostimulants in Patients with Dementia. Ann Pharmacother 2010;44:1624–32.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Young JJ,
    2. Lavakumar M,
    3. Tampi D,
    4. Balachandran S,
    5. Tampi RR
    . Frontotemporal dementia: latest evidence and clinical implications. Ther Adv Psychopharmacol 2018;8:33–48.
    OpenUrl
  33. 33.↵
    1. Sassi KLM,
    2. Rocha NP,
    3. Colpo GD,
    4. John V,
    5. Teixeira AL
    . Amphetamine use in the elderly: a systematic review of the literature. Curr Neuropharmacol 2020;18:126–35.
    OpenUrl
  34. 34.↵
    1. Torgersen T,
    2. Gjervan B,
    3. Lensing MB,
    4. Rasmussen K
    . Optimal management of ADHD in older adults. Neuropsychiatr Dis Treat 2016;12:
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Keywords